Mild cognitive impairment (MCI): Nutritional, Infectious, Autoimmune and Miscellaneous Triggers and Mimickers: A Tactical Metabolomics and Precision Neurology Map Against Alzheimer’s Disease 2nd Edition
Mild Cognitive Impairment (MCI): Nutritional, Infectious, Autoimmune and Miscellaneous Triggers and Mimickers: A Tactical Metabolomics and Precision Neurology Map Against Alzheimer's Disease (ADRD)By Neurologist Óscar Mancera PáezMild Cognitive Impairment (MCI) represents one of the most challenging crossroads in modern neurology. While some individuals with MCI will eventually progress to Alzheimer's disease or another neurodegenerative disorder, many experience cognitive decline driven by potentially reversible metabolic, nutritional, infectious, autoimmune, endocrine, toxic, vascular, or systemic conditions. Distinguishing these entities early is one of the greatest opportunities—and responsibilities—of precision neurology.This book presents a comprehensive clinical framework that moves beyond the traditional amyloid- and tau-centered paradigm to embrace metabolomics, systems biology, and precision neurology as powerful tools for identifying the biological mechanisms underlying cognitive impairment. Rather than viewing MCI as a single disease, the author approaches it as a clinical syndrome resulting from diverse molecular pathways that require individualized investigation.At the center of this work is the concept of a Tactical Metabolomics and Precision Neurology Map, an integrated diagnostic strategy that combines clinical neurology with metabolic profiling, neuroimmunology, microbiology, genetics, and multi-omics technologies. This map enables clinicians to identify disturbances in metabolic, inflammatory, mitochondrial, neurotransmitter, lipid, endocrine, and immune networks long before irreversible neuronal injury develops.The book explores how metabolomics provides a real-time biochemical portrait of cellular physiology, bridging the gap between genetic predisposition and clinical disease. Alterations in glucose utilization, mitochondrial energy production, amino acid metabolism, lipid homeostasis, oxidative stress, and neuroinflammation frequently precede structural brain changes by many years. When integrated with genomic, transcriptomic, proteomic, imaging, and biomarker data, these metabolic signatures offer unprecedented opportunities for early diagnosis, differential diagnosis, risk stratification, and precision therapeutic planning.Unlike conventional texts that focus primarily on Alzheimer's pathology, this volume systematically examines the numerous disorders capable of mimicking or precipitating MCI, including: Nutritional deficiencies and metabolic disorders Autoimmune and paraneoplastic encephalopathies Chronic infectious diseases affecting the central nervous system Endocrine dysfunctions Toxic and environmental exposures Sleep disorders Cerebrovascular disease Medication-induced cognitive impairment Mitochondrial disorders Systemic inflammatory diseases Neuropsychiatric conditions Other reversible and partially reversible causes of cognitive decline Each condition is analyzed through the lens of precision neurology, emphasizing its metabolic fingerprint, underlying pathophysiology, characteristic biomarkers, neuroimaging findings, differential diagnosis, and evidence-based management strategies.The tactical metabolomics framework described throughout this book highlights several fundamental biological domains involved in Alzheimer's disease and related dementias (ADRD), including: Energetic failure, characterized by impaired cerebral glucose metabolism and mitochondrial dysfunction that compromise neuronal resilience. Lipid dysregulation, involving alterations in sphingolipids, phospholipids, ceramides, and acylcarnitines that disrupt membrane integrity, synaptic function, and cellular signaling. Neurotransmitter imbalance, reflected by abnormalities in metabolites such as N-acetylaspartate, glutamate, GABA, and aromatic amino acids, indicating dysfunction of excitatory and inhibitory neural circuits. Immune and inflammatory activation, where chronic neuroinflammation alters metabolic pathways and accelerates neurodegeneration. Oxidative stress and redox imbalance, contributing to progressive neuronal injury and impaired cellular repair mechanisms. The book also demonstrates how integrating metabolomic data with established genetic risk factors—including APP, PSEN1, PSEN2, APOE ε4, TREM2, and other susceptibility genes—enhances diagnostic precision and improves prediction of disease progression. Rather than treating genetics as destiny, the author illustrates how genetic variants interact dynamically with metabolism, environment, lifestyle, nutrition, infection, and immunity to shape each patient's unique cognitive trajectory.One of the central themes is that early detection transforms outcomes. Metabolic abnormalities may emerge 10 to 25 years before clinical dementia, creating a valuable therapeutic window during which targeted interventions may preserve neuronal function, delay progression, or even reverse cognitive symptoms when the underlying cause is treatable.Designed for neurologists, geriatricians, psychiatrists, internists, primary care physicians, neuroscientists, clinical laboratory professionals, and advanced healthcare practitioners, this book combines rigorous scientific evidence with practical clinical algorithms. Numerous tables, diagnostic pathways, biomarker panels, differential diagnosis frameworks, and precision medicine strategies provide a bedside resource for evaluating patients with cognitive complaints.Ultimately, Mild Cognitive Impairment (MCI): Nutritional, Infectious, Autoimmune and Miscellaneous Triggers and Mimickers advocates for a paradigm shift—from diagnosing dementia after irreversible neuronal loss has occurred to identifying the molecular disturbances that precede it. By integrating metabolomics, multi-omics, clinical neurology, and systems medicine, this tactical roadmap equips clinicians to distinguish Alzheimer's disease from its many mimickers, uncover reversible causes of cognitive decline, and deliver truly personalized neurological care in the era of precision medicine.
Get it → ayudante6.gumroad.com